Digital Biomarkers: Unlocking New Insights in Disease Management and Drug Development

This report delivers a comprehensive analysis of the evolving role of digital biomarkers in pharmaceutical research, drug development and disease management. Based on in-depth interviews with leading experts, it explores how advances in wearable devices, biosensors and AI-driven analytics are enabling continuous, objective and patient-centric data to enhance clinical trials and real-world evidence generation.

The report explores the integration of digital endpoints into clinical development, the regulatory frameworks and validation challenges shaping their use, and the impact of digital biomarkers on patient monitoring, compliance and personalised medicine. It also considers collaborative strategies, emerging therapeutic use cases and the future trends influencing adoption across the biopharma landscape. Gain actionable insights into the opportunities and challenges of implementing digital biomarker strategies to support more efficient, data-driven and value-based healthcare.

Key Questions Answered:

• 1. How are digital biomarkers unlocking new insights in drug development and disease management?
• 2. In what ways are pharmaceutical companies using digital biomarkers to enhance clinical development?
• 3. What are the main challenges in validating and qualifying digital biomarkers for clinical use?
• 4. Where have digital biomarkers been successfully deployed to drive drug development programs?
• 5. How are digital biomarkers supporting disease management and patient care?
• 6. What are the latest trends in the adoption and application of digital biomarkers in pharma?
• 7. What future opportunities exist for biopharma to leverage digital biomarkers for improved outcomes?
• 8. How can digital biomarkers support the reimbursement of innovative medicines?
• 9. What are the key considerations for ensuring digital biomarkers are fit-for-purpose?
• 10. How are pharma companies collaborating and investing to advance digital biomarker strategies?

Key Companies:

Partial List of Participating Experts:

• Vice President, Clinical Outcome Assessment Program, Critical Path Institute, US
• Vice President, Critical Path Institute, US
• Executive Scientific Director, Research & Strategy, Modus Outcomes, US
• Science Director, VivoSense, Switzerland
• Vice President of Data Science, Mitra bio, UK
• Scientific Director, Tecniplast, Germany

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.